Mary  Reumuth net worth and biography

Mary Reumuth Biography and Net Worth

CFO of KALA BIO
Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.

How old is Mary Reumuth?

Ms. Reumuth is currently 49 years old. There are 6 older executives and no younger executives at KALA BIO. The oldest executive at KALA BIO is Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer, who is 71 years old. Learn More on Mary Reumuth's age.

How do I contact Mary Reumuth?

The corporate mailing address for Ms. Reumuth and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at [email protected]. Learn More on Mary Reumuth's contact information.

Has Mary Reumuth been buying or selling shares of KALA BIO?

Mary Reumuth has not been actively trading shares of KALA BIO within the last three months. Most recently, Mary Reumuth sold 2,850 shares of the business's stock in a transaction on Tuesday, January 4th. The shares were sold at an average price of $1.30, for a transaction totalling $3,705.00. Learn More on Mary Reumuth's trading history.

Who are KALA BIO's active insiders?

KALA BIO's insider roster includes Todd Bazemore (COO), Romulus Brazzell (Insider), Hongming Chen (Insider), Mark Iwicki (CEO), and Mary Reumuth (CFO). Learn More on KALA BIO's active insiders.

Are insiders buying or selling shares of KALA BIO?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 5,766 shares worth more than $38,817.45. The most recent insider tranaction occured on January, 4th when insider Eric Trachtenberg sold 1,227 shares worth more than $8,269.98. Insiders at KALA BIO own 13.4% of the company. Learn More about insider trades at KALA BIO.

Information on this page was last updated on 1/4/2024.

Mary Reumuth Insider Trading History at KALA BIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2022Sell2,850$1.30$3,705.00View SEC Filing Icon  
See Full Table

Mary Reumuth Buying and Selling Activity at KALA BIO

This chart shows Mary Reumuth's buying and selling at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KALA BIO Company Overview

KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $6.59
Low: $6.43
High: $6.83

50 Day Range

MA: $7.46
Low: $6.77
High: $7.99

2 Week Range

Now: $6.59
Low: $5.10
High: $19.35

Volume

7,567 shs

Average Volume

26,459 shs

Market Capitalization

$18.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A